How can advanced diagnostics and therapies (e.g., HVPG, NGAL/KIM-1, TIPS, terlipressin) be adapted for effective use in resource-limited settings with a high cirrhosis burden? The gene discussed is HAVCR1; the disease is Cirrhosis.